Attached files
file | filename |
---|---|
EX-99.1 - EXHIBIT 99.1 - Riot Blockchain, Inc. | ex99x1.htm |
EX-99.2 - EXHIBIT 99.2 - Riot Blockchain, Inc. | ex99x2.htm |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of
The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported) August 15, 2012
AspenBio Pharma, Inc.
|
(Exact name of registrant as specified in charter)
|
Colorado
|
001-33675
|
84-155338
|
(State or other jurisdiction of incorporation or
organization)
|
(Commission File Number)
|
(IRS Employer Identification No.)
|
1585 South Perry Street, Castle Rock, CO
|
80104
|
(Address of principal executive offices)
|
(Zip Code)
|
Registrant’s telephone number, including area code (303) 794-2000
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 8.01. Other Events.
On August 15, 2012, AspenBio Pharma, Inc. (the “Company”) issued a press release titled — “AspenBio Pharma Focuses Resources on Development of AppyScoreTM Clinical Diagnostic Test.” The press release is furnished as Exhibit 99.1 to this Form 8-K.
On August 15, 2012, AspenBio Pharma, Inc. (the “Company”) hosted an investor update call — “AspenBio Pharma August 15, 2012 Conference Call.” The script for this call is furnished as Exhibit 99.2 to this Form 8-K.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits
Exhibits
99.1
|
Press release dated August 15, 2012, issued by AspenBio Pharma, Inc. Titled “AspenBio Pharma Focuses Resources on Development of AppyScoreTM Clinical Diagnostic Test”
|
99.2
|
Investor conference call script dated August 15, 2012
|
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
AspenBio Pharma, Inc.
(Registrant)
|
||
Date: August 16, 2012
|
By:
|
/s/ Jeffrey G. McGonegal
|
Name: Jeffrey G. McGonegal
|
||
Title: Chief Financial Officer
|